NLS Pharmaceutics (NASDAQ:NLSP) announces that it has entered into a License Agreement with Novartis Pharma AG, for all of the available data in the original NDA for Sanorex (mazindol) submitted to the U.S. FDA in February 1972 Share your opinion in the comments and support the idea with likes. Thank you for your support!
If NLS can confirm the demand used to move into the current resistance as support, it could break the current supply level and remain in the upper channel until earnings.
NLS broke out from a cup w/ handle pattern on heavy volume. It recently came back down to retest the breakout area and bounced strongly off the 10-day moving average. Really great entry this morning for those who missed the original breakout or those wanting to add.
Adjustments made from my previous chart. NLS could end up moving a little faster than I thought. Just adding a faster move into the chart
Trend projection on NLS post earnings with down side rejection and potential upside moves
Sympathy move on $PTON acquisition, these guys make exercise equipment and could potentially form partnerships with other players in the space, who knows.
We'll see how this one goes. Entering here. Still playing with pitchforks and learning.
i read about natilus from this idea and turned my chiggen nugget into a six-piece chiggen nuggets meal: to be tbh with you, i had the same idea above natilus too but kept it to myself, but now that i see ppls talking about it i wanna shares my cool profit ideas with my home dog(s) lets think about the future wen before pandemics hits, i walk by BALLET TOTALS...
Bought @ 5.39 SL (soft) 5.06 Long term Target 11.2. Possible lower target 10. Will be watching volume and for bearish signals there. Weekly and Daily look primed for a bottom/bounce. Keep an eye on bearish divergences after bounce because monthly still looks bearish and a high value buying area exists below 3.5 Higher risk trade. So lower position size for...
Buy on pullback to demand zone. Note: Demand zone is not fresh. Entry: $17.06 Stop Loss: $ 16.60 Target 1: $20.00